Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports
DOI:
https://doi.org/10.2340/actadv.v104.40634Keywords:
nemolizumab, atopic dermatitis, bullous pemphigoid, itch, IL-31Abstract
Abstract is missing (Short communication)
Downloads
References
Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPSG. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141-150.
https://doi.org/10.1056/NEJMoa1917006
Watanabe Y, Ishiuji Y, Ogawa-Tominaga M, Katsuta M, Asahina A. Real-world clinical efficacy of nemolizumab in Japanese patients with atopic dermatitis. Itch 2023; 33: 691-692.
https://doi.org/10.1097/itx.0000000000000071
Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPaSG. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 2022; 186: 642-651.
https://doi.org/10.1111/bjd.20873
Masuyuki R, Sato E, Imafuku S. A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody. J Dermatol 2024 Mar 20 [Online ahead of print].
https://doi.org/10.1111/1346-8138.17171
Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861-868.
https://doi.org/10.1111/j.1365-2133.2009.09300.x
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.
https://doi.org/10.3389/fimmu.2019.01238
Rüdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol 2018; 98: 766-771.
https://doi.org/10.2340/00015555-2951
Fassett MS, Braz JM, Castellanos CA, Salvatierra JJ, Sadeghi M, Yu X, et al. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci Immunol 2023; 8: eabi6887.
https://doi.org/10.1126/sciimmunol.abi6887
Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 2003; 148: 203-210.
Downloads
Published
How to Cite
License
Copyright (c) 2024 Michie Katsuta, Ryoichi Kamide, Yozo Ishiuji, Yoshimasa Nobeyama, Akihiko Asahina
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
